PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases - Archive ouverte HAL Access content directly
Journal Articles Pharmaceutics Year : 2021

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

(1, 2) , (1) , (1) , (2)
1
2

Abstract

Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).
Fichier principal
Vignette du fichier
pharmaceutics-13-01042-1.pdf (1.96 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

inserm-03285083 , version 1 (13-07-2021)

Identifiers

Cite

Anthony Cunha, Alexandra Gaubert, Laurent Latxague, Benjamin Dehay. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics, 2021, 13 (7), pp.1042. ⟨10.3390/pharmaceutics13071042⟩. ⟨inserm-03285083⟩
14 View
41 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More